Skip to main content

Day: May 18, 2020

Soprano sai maksun koulutusvientisopimuksesta

Soprano Oyj sisäpiiritieto 18.5.2020 klo 15.05Soprano sai maksun koulutusvientisopimuksestaSoprano on saanut 1,2 miljoonan euron suorituksen merkittävän koulutusvientisopimuksen mukaisesti pankkitililleen. Yhtiö tiedotti 21.4.2020 allekirjoittaneensa koulutusvientisopimuksen valtiollisen toimijan kanssa. Sopimuksen mukaisesti ensimmäinen 30 prosentin erä on nyt maksettu ja loput 70 prosenttia maksetaan arviolta joulukuussa 2020.Lisätietoja: Soprano Oyj,Toimitusjohtaja Arto Tenhunen, 0400 413 314, arto.tenhunen@soprano.fiTalousjohtaja Panu Kauppinen, 044 236 3740, panu.kauppinen@soprano.fiSoprano Group – Lifelong Learning for Working Professionals 

Continue reading

Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1×1 Investor Conference, June 15-16, 2020.Raj Mehra, Ph.D., Chairman and CEO, will host meetings via conference calls.For additional information about the Benchmark Company Healthcare House Call Virtual Video 1×1 Investor Conference: https://benchmark-healthcare-house-call-virtual.events.issuerdirect.com/About Seelos Therapeutics:Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the...

Continue reading

Inovalon To Participate in the SunTrust Robinson Humphrey Virtual Meeting Series

BOWIE, Md., May 18, 2020 (GLOBE NEWSWIRE) — Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will participate in a fireside chat at the SunTrust Robinson Humphrey Virtual Meeting Series, hosted by analyst, Sandy Draper.The fireside chat will take place on Friday, May 22, 2020 at 1:00pm ET.  Investors may access the live and archived audio session by using the following link:https://www.netroadshow.com/conferencing/login?show=cb41fd4e&confId=17667A replay of the event will be available for one week on the Investor Relations section of Inovalon’s website at www.inovalon.com.About InovalonInovalon is a leading...

Continue reading

Acreage Announces Operational Update to Drive Improved Margins and Returns

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE: ACRG.U) (OTCQX: ACRGF) (FSE: 0VZ) today announced the sale of certain non-core assets as part of an update to its overall strategic plan to focus on key, profitable operations. The Company expects this shift in focus will lead to immediate margin improvements and accelerate its pathway to achieve positive pro-forma adjusted EBITDA for the full year 2020.The strategic shift is a direct response to significant changes in capital markets, and in anticipation of continued historic pressure on consumer sentiment and regional and national economic uncertainties. In addition to the sale of some non-core and other under-performing assets, Acreage intends to operate with a more optimized overhead cost structure and corporate team to adapt...

Continue reading

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adultsThe longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages and SMA typesNew data add to the significant body of evidence underscoring the clinically meaningful and sustained benefit of SPINRAZA in toddlers, children and young adults treated for up to six and a half yearsCAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced additional data from the SPINRAZA (nusinersen) clinical development program that further demonstrate the sustained efficacy and longer-term safety of SPINRAZA in a broad range of patients with spinal muscular atrophy (SMA). These new data were selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting and...

Continue reading

Applied Materials to Participate at Upcoming Investor Conferences

SANTA CLARA, Calif., May 18, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that Gary Dickerson, President and CEO, and Dan Durn, Senior Vice President and CFO, will participate in a virtual fireside chat at the Bernstein Strategic Decisions Conference on Wednesday, May 27 beginning at 11:30 a.m. PT / 2:30 p.m. ET.Additionally, Mr. Durn will participate in virtual fireside chats at the following investor conferences:Needham Virtual Technology and Media Conference on Wednesday, May 20 beginning at 9:15 a.m. PT / 12:15 p.m. ET.Cowen 2020 Virtual Technology, Media and Telecom Conference on Thursday, May 28 beginning at 8:50 a.m. PT / 11:50 a.m. ET.BofA Securities Global Technology Conference on Wednesday, June 3 beginning at 7:00 a.m. PT / 10:00 a.m. ET.A live audio webcast of these sessions will be available on the...

Continue reading

Reliance Global Group Appoints David Lazar to Board of Directors

LAKEWOOD, NJ, May 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ Reliance Global Group, Inc. (OTCQB: RELI) (“RELI” or the “Company”) today announced the appointment of David Lazar as an independent member of the Company’s Board of Directors. As a result, the Board of Directors has increased to 5 members, including 3 independent directors, thereby meeting the independence requirements for a national exchange.Mr. Lazar brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions. Mr. Lazar is currently the CEO of both Custodian Ventures LLC & Activist Investing LLC, which specialize in reverse merger and other event-driven opportunities. Ezra Beyman, CEO of Reliance Global Group, stated, “We are...

Continue reading

Strongbridge Biopharma plc to Present at Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series

DUBLIN, Ireland and TREVOSE, Pa., May 18, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the management team will present at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. Details are as follows:Date/Time: Tuesday, May 26, 2020 at 12:00 p.m. EDTTo access the presentation, please login here: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/38244/indexl.htmlThe Company’s presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.About Strongbridge BiopharmaStrongbridge Biopharma is...

Continue reading

Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery

CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has appointed Kenneth Rhodes, PhD, as Senior Vice President, Therapeutics Discovery. In this newly created position, Dr. Rhodes will be responsible for defining the strategy and guiding discovery research to design new therapeutic candidates and advance them to the clinic, with an initial focus on neurological diseases.“Ken is joining Wave at an exciting time for the company, when we are making chemistry advancements and developing new modalities with our PRISM platform that have the potential to expand our pipeline with innovative stereopure oligonucleotides to treat intractable neurological...

Continue reading

Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

 Sub-distributor has network of state and local government clients seeking testing solutions Return to Church program being initiated in Orlando, Fla. areaREHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced its first commercial sale of COVID-19 tests.  The sale was made via a sub-distribution agreement with a U.S.-based medical distribution company with clients in state and local governments throughout the Southeastern United States who are seeking comprehensive testing solutions for Return-to-Work programs....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.